AMR Roundtable Part 2: The Need For Patient Perspectives To Reinforce Urgency Of Antimicrobial Drug Development
Executive Summary
Scrip spoke with the CEOs of Zavante and Amplyx as well as a BARDA official during a roundtable discussion at BIO about the challenges of antimicrobial drug development. This second part of the roundtable centers on the lack of patient advocates in the area of antimicrobial-resistant infections.
You may also be interested in...
WHO Publishes List Of Pathogen Threats To Rouse Drug Developers
The World Health Organisation has released a list of 12 bacteria it says pose the greatest threat to human health as a way of urging governments and the drug development industry to incentivize and launch an R&D response against the increasing global issue of antibiotic resistance.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.